Inactive Instrument

IR-Med Inc. Stock Other OTC

Equities

IRME

US46265R1032

Medical Equipment, Supplies & Distribution

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 1M 1.36M Sales 2025 * 9.25M 12.62M Capitalization 40.94M 55.86M
Net income 2024 * -3M -4.09M Net income 2025 * 1M 1.36M EV / Sales 2024 * 40.9 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 4.43 x
P/E ratio 2024 *
-11.7 x
P/E ratio 2025 *
19.5 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 31.5%
More Fundamentals * Assessed data
Dynamic Chart
IR-Med Inc.'S PressureSafe Receives FDA Listing for the Indication of Decision Support Device for Pressure Injuries CI
IR-Med Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IR-Med Inc. and I.R Med Ltd. Appoints Aharon Klein as Interim Chief Executive Officer CI
IR-Med Inc. Announces Cessation of Tzur Di-Cori Pursuant as Chief Executive Officer CI
IR-Med Inc. Announces Resignation of Inna Martin as Director CI
IR-MED to Report New Clinical Efficacy Data for Detection of Pressure Injuries with its AI- Based PressureSafe? Device at NPIAP 2024 Annual Conference on February 16 CI
IR-Med Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
IR-MED Announces Executive Changes Effective as of October 15, 2023 CI
Ir-Med to Conduct Usability Study with Methodist Healthcare of San Antonio for Its Pressuresafe Device Which Is Slated for U.S. Launch in H1 2024 CI
IR-Med Inc. Appoints Richard Serbin, Esq. to Its Advisory Board CI
IR-Med Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Ir-Med Inc. Announces Interim Results from A Clinical Study of Pressuresafe CI
IR-Med Inc. Appoints Lynn Eschenbacher to its Advisory Board CI
IR-Med Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
IR-Med Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
More news
Managers TitleAgeSince
Chief Executive Officer 60 -
Founder 77 -
Director of Finance/CFO 50 -
Members of the board TitleAgeSince
Founder 77 -
Director/Board Member 53 -
Director/Board Member 59 21-02-28
More insiders
IR-Med, Inc. is a development-stage medical device company. The Company is engaged in developing its technology through its subsidiary and is utilizing Infra-Red-light spectroscopy (IR) combined with artificial intelligence (AI) technology platform to develop non-invasive devices for various medical indications, by detecting and measuring various biomarkers and molecules in the blood and in human tissue in real-time. The Company has three principal medical devices in development. Its product under development, PressureSafe, is a handheld optical monitoring device that is being developed to support early detection of pressure injuries (PI) to the skin and underlying tissue. DiaSafe is a handheld optical monitoring device that is being developed to support early detection of DFUs in lower limb skin and underlying tissue. Nobiotics is an otoscope designed to support physicians with an immediate indication as to whether a mid-ear infection (otitis media) is of a bacterial origin.
More about the company
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW